Table 4.
Study | Sample | Dosing | Outcomes |
---|---|---|---|
McClure et al30 (2014) | N = 116 adolescents (age 15 to 21) with cannabis dependence (72% male, 84% white; 59% smokers) | 1,200 mg twice daily (2,400 mg/d) vs placebo for 8 weeks (double-blind) added to contingency management | No group differences in reported cigarettes smoked |
Froeliger et al31 (2015) | N = 16 adult smokers (69% male; 56% black/African American, 44% white) | 1,200 mg twice daily (2,400 mg/d) vs placebo for 3.5 days (double- blind) |
|
Prado et al32 (2015) | N = 34 outpatients with therapy-resistant tobacco use disorder (26.5% male) | 1,500 mg twice daily (3,000 mg/d) vs placebo for 12 weeks (double-blind) | NAC group reported fewer cigarettes and had lower carbon monoxide levels at end of treatment, compared with placebo group |
Knackstedt et al33 (2009) | N = 33 adults with nicotine dependence (58% male; 70% white, 21% black/African American) | 1,200 mg twice daily (2,400 mg/d) vs placebo for 4 weeks (double-blind) |
|
Grant et al34 (2014) | N = 28 adults with nicotine dependence and pathological gambling (82% male; 82% white) | 1,200 to 3,000 mg/d (titrated based on clinician’s judgment) vs placebo for 12 weeks (double-blind) | NAC group reported fewer symptoms of nicotine dependence in first half of treatment |
Schmaal et al35 (2011) | N = 22 undergraduate smokers (41% male) | 1,800 mg twice daily for 3 days (3,600 mg/d) and once on Day 4 (1,800 mg) vs placebo (double-blind) |
|
Bernardo et al36 (2009) | N = 75 adults with bipolar disorder (30% male; 45% smokers) | 1,000 mg twice daily (2,000 mg/d) vs placebo for 6 months (double-blind) | No group differences in self-reported frequency of tobacco use |
NAC: N-acetylcysteine